APO Research
Talk to an analyst

APO RESEARCH · REPORT

Single Nucleotide Polymorphism (SNP) Genotyping

Single Nucleotide Polymorphism (SNP) Genotyping is the measurement of genetic variations of single nucleotide polymorphisms (SNPs) between members of a species. It is a form of genotyping, which is the measurement of more general genetic variation. SNP genotyping is not only the genetic markers present in most, but also the most promising markers. SNP genotyping as the most potential for development of molecular markers, it cans achieve large-scale highly automated, thus it is more suited to a huge number of detection and analysis, has been widely used in biology, agriculture, medicine, biological evolution and other fields.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Single Nucleotide Polymorphism (SNP) Genotyping is the measurement of genetic variations of single nucleotide polymorphisms (SNPs) between members of a species. It is a form of genotyping, which is the measurement of more general genetic variation. SNP genotyping is not only the genetic markers present in most, but also the most promising markers. SNP genotyping as the most potential for development of molecular markers, it cans achieve large-scale highly automated, thus it is more suited to a huge number of detection and analysis, has been widely used in biology, agriculture, medicine, biological evolution and other fields.

Selected research

Market Outlook & Growth Opportunities

Global Single Nucleotide Polymorphism (SNP) Genotyping Market Outlook and Growth Opportunities 2026

21 December 2025215 pages

Choose your research edition.

Industry ResearchSingle Nucleotide Polymorphism (SNP) Genotyping Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Single Nucleotide Polymorphism (SNP) Genotyping Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Single Nucleotide Polymorphism (SNP) Genotyping Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Single Nucleotide Polymorphism (SNP) Genotyping Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Single Nucleotide Polymorphism (SNP) Genotyping Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

Single Nucleotide Polymorphism (SNP) Genotyping is the measurement of genetic variations of single nucleotide polymorphisms (SNPs) between members of a species. It is a form of genotyping, which is the measurement of more general genetic variation. SNP genotyping is not only the genetic markers present in most, but also the most promising markers. SNP genotyping as the most potential for development of molecular markers, it cans achieve large-scale highly automated, thus it is more suited to a huge number of detection and analysis, has been widely used in biology, agriculture, medicine, biological evolution and other fields.

Global Single Nucleotide Polymorphism (SNP) Genotyping key players include Illumina, Affymetrix, Applied Biosystems, Agilent Technologies, Beckman Coulter, etc. Global top five players hold a share about 65%.

North America is the largest market, with a share about 40%, followed by Europe and Japan, having a total share about 35 percent.

Read the full market overview

In terms of product, the segment includes Transversion, Transition. And in terms of application, the largest application is Diagnostics, followed by Animal, Plant, Research, etc.

This report provides an overview of the global Single Nucleotide Polymorphism (SNP) Genotyping market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Single Nucleotide Polymorphism (SNP) Genotyping and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Single Nucleotide Polymorphism (SNP) Genotyping revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Single Nucleotide Polymorphism (SNP) Genotyping market.

Single Nucleotide Polymorphism (SNP) Genotyping Segment by Company

Illumina

Affymetrix

Applied Biosystems

Agilent Technologies

Beckman Coulter

Roche

Qiagen

Luminex Corporation

Enzo Life Sciences

Bio-rad

Sequenom

Ocimum Biosolutions

GE Healthcare

GenScript

Douglas Scientific

BGI

Beijing Sunbiotech

HuaGene Biotech

Generay Biotech

Benegene

Shanghai Biochip

GENESKY

HD Biosciences

Single Nucleotide Polymorphism (SNP) Genotyping Segment by Type

Transversion

Transition

Single Nucleotide Polymorphism (SNP) Genotyping Segment by Application

Diagnostics

Animal

Plant

Research

Others

Single Nucleotide Polymorphism (SNP) Genotyping Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Single Nucleotide Polymorphism (SNP) Genotyping status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Single Nucleotide Polymorphism (SNP) Genotyping key companies, revenue, market share, and recent developments.

3. To split the Single Nucleotide Polymorphism (SNP) Genotyping breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Single Nucleotide Polymorphism (SNP) Genotyping market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Single Nucleotide Polymorphism (SNP) Genotyping significant trends, drivers, influence factors in global and regions.

6. To analyze Single Nucleotide Polymorphism (SNP) Genotyping competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Single Nucleotide Polymorphism (SNP) Genotyping market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Single Nucleotide Polymorphism (SNP) Genotyping and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Single Nucleotide Polymorphism (SNP) Genotyping.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Single Nucleotide Polymorphism (SNP) Genotyping industry.

Chapter 3: Detailed analysis of Single Nucleotide Polymorphism (SNP) Genotyping company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Single Nucleotide Polymorphism (SNP) Genotyping in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Single Nucleotide Polymorphism (SNP) Genotyping in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Single Nucleotide Polymorphism (SNP) Genotyping Industry Trends Table 2. Single Nucleotide Polymorphism (SNP) Genotyping Industry Drivers Table 3. Single Nucleotide Polymorphism (SNP) Genotyping Industry Opportunities and Challenges Table 4. Single Nucleotide Polymorphism (SNP) Genotyping Industry Restraints Table 5. Global Single Nucleotide Polymorphism (SNP) Genotyping Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Single Nucleotide Polymorphism (SNP) Genotyping Revenue Share by Company (2021-2026) Table 7. Global Single Nucleotide Polymorphism (SNP) Genotyping Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Single Nucleotide Polymorphism (SNP) Genotyping Key Company Manufacturing Base & Headquarters Table 9. Global Single Nucleotide Polymorphism (SNP) Genotyping Company, Product Type & Application Table 10. Global Single Nucleotide Polymorphism (SNP) Genotyping Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Single Nucleotide Polymorphism (SNP) Genotyping by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Transversion Table 15. Significant Companies of Transition Table 16. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type (2021-2026) Table 20. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Diagnostics Table 22. Significant Companies of Animal Table 23. Significant Companies of Plant Table 24. Significant Companies of Research Table 25. Significant Companies of Others Table 26. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application (2021-2026) Table 30. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application (2027-2032) Table 31. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Region (2021-2026) Table 34. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Region (2027-2032) Table 36. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Market Share by Country (2021-2026) Table 39. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Market Share by Country (2027-2032) Table 41. Illumina Company Information Table 42. Illumina Business Overview Table 43. Illumina Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Illumina Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 45. Illumina Recent Development Table 46. Affymetrix Company Information Table 47. Affymetrix Business Overview Table 48. Affymetrix Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Affymetrix Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 50. Affymetrix Recent Development Table 51. Applied Biosystems Company Information Table 52. Applied Biosystems Business Overview Table 53. Applied Biosystems Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Applied Biosystems Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 55. Applied Biosystems Recent Development Table 56. Agilent Technologies Company Information Table 57. Agilent Technologies Business Overview Table 58. Agilent Technologies Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Agilent Technologies Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 60. Agilent Technologies Recent Development Table 61. Beckman Coulter Company Information Table 62. Beckman Coulter Business Overview Table 63. Beckman Coulter Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Beckman Coulter Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 65. Beckman Coulter Recent Development Table 66. Roche Company Information Table 67. Roche Business Overview Table 68. Roche Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Roche Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 70. Roche Recent Development Table 71. Qiagen Company Information Table 72. Qiagen Business Overview Table 73. Qiagen Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Qiagen Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 75. Qiagen Recent Development Table 76. Luminex Corporation Company Information Table 77. Luminex Corporation Business Overview Table 78. Luminex Corporation Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Luminex Corporation Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 80. Luminex Corporation Recent Development Table 81. Enzo Life Sciences Company Information Table 82. Enzo Life Sciences Business Overview Table 83. Enzo Life Sciences Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Enzo Life Sciences Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 85. Enzo Life Sciences Recent Development Table 86. Bio-rad Company Information Table 87. Bio-rad Business Overview Table 88. Bio-rad Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Bio-rad Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 90. Bio-rad Recent Development Table 91. Sequenom Company Information Table 92. Sequenom Business Overview Table 93. Sequenom Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. Sequenom Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 95. Sequenom Recent Development Table 96. Ocimum Biosolutions Company Information Table 97. Ocimum Biosolutions Business Overview Table 98. Ocimum Biosolutions Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Ocimum Biosolutions Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 100. Ocimum Biosolutions Recent Development Table 101. GE Healthcare Company Information Table 102. GE Healthcare Business Overview Table 103. GE Healthcare Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. GE Healthcare Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 105. GE Healthcare Recent Development Table 106. GenScript Company Information Table 107. GenScript Business Overview Table 108. GenScript Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 109. GenScript Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 110. GenScript Recent Development Table 111. Douglas Scientific Company Information Table 112. Douglas Scientific Business Overview Table 113. Douglas Scientific Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 114. Douglas Scientific Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 115. Douglas Scientific Recent Development Table 116. BGI Company Information Table 117. BGI Business Overview Table 118. BGI Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 119. BGI Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 120. BGI Recent Development Table 121. Beijing Sunbiotech Company Information Table 122. Beijing Sunbiotech Business Overview Table 123. Beijing Sunbiotech Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 124. Beijing Sunbiotech Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 125. Beijing Sunbiotech Recent Development Table 126. HuaGene Biotech Company Information Table 127. HuaGene Biotech Business Overview Table 128. HuaGene Biotech Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 129. HuaGene Biotech Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 130. HuaGene Biotech Recent Development Table 131. Generay Biotech Company Information Table 132. Generay Biotech Business Overview Table 133. Generay Biotech Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 134. Generay Biotech Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 135. Generay Biotech Recent Development Table 136. Benegene Company Information Table 137. Benegene Business Overview Table 138. Benegene Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 139. Benegene Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 140. Benegene Recent Development Table 141. Shanghai Biochip Company Information Table 142. Shanghai Biochip Business Overview Table 143. Shanghai Biochip Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 144. Shanghai Biochip Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 145. Shanghai Biochip Recent Development Table 146. GENESKY Company Information Table 147. GENESKY Business Overview Table 148. GENESKY Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 149. GENESKY Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 150. GENESKY Recent Development Table 151. HD Biosciences Company Information Table 152. HD Biosciences Business Overview Table 153. HD Biosciences Single Nucleotide Polymorphism (SNP) Genotyping Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 154. HD Biosciences Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio Table 155. HD Biosciences Recent Development Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Single Nucleotide Polymorphism (SNP) Genotyping Product Image Figure 2. Global Single Nucleotide Polymorphism (SNP) Genotyping Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Single Nucleotide Polymorphism (SNP) Genotyping Market Size (2021-2032) & (US$ Million) Figure 4. Global Single Nucleotide Polymorphism (SNP) Genotyping Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Transversion Image Figure 8. Transition Image Figure 9. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type (2021-2032) Figure 12. Diagnostics Image Figure 13. Animal Image Figure 14. Plant Image Figure 15. Research Image Figure 16. Others Image Figure 17. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application (2021-2032) Figure 20. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2021-2032) & (US$ Million) Figure 23. North America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2021-2032) & (US$ Million) Figure 29. South America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Transversion
  • Transition
Applications
  • Diagnostics
  • Animal
  • Plant
  • Research
  • Others
Companies covered
  • Illumina
  • Affymetrix
  • Applied Biosystems
  • Agilent Technologies
  • Beckman Coulter
  • Roche
  • Qiagen
  • Luminex Corporation
  • Enzo Life Sciences
  • Bio-rad
  • Sequenom
  • Ocimum Biosolutions
  • GE Healthcare
  • GenScript
  • Douglas Scientific
  • BGI
  • Beijing Sunbiotech
  • HuaGene Biotech
  • Generay Biotech
  • Benegene
  • Shanghai Biochip
  • GENESKY
  • HD Biosciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Single Nucleotide Polymorphism (SNP) Genotyping Market Dynamics
  1. 2.1 Single Nucleotide Polymorphism (SNP) Genotyping Industry Trends
  2. 2.2 Single Nucleotide Polymorphism (SNP) Genotyping Industry Drivers
  3. 2.3 Single Nucleotide Polymorphism (SNP) Genotyping Industry Opportunities and Challenges
  4. 2.4 Single Nucleotide Polymorphism (SNP) Genotyping Industry Restraints
3 Single Nucleotide Polymorphism (SNP) Genotyping Market by Company
  1. 3.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Company Revenue Ranking in 2025
  2. 3.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Revenue by Company (2021-2026)
  3. 3.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Company Ranking (2024-2026)
  4. 3.4 Global Single Nucleotide Polymorphism (SNP) Genotyping Company Manufacturing Base and Headquarters
  5. 3.5 Global Single Nucleotide Polymorphism (SNP) Genotyping Company Product Type and Application
  6. 3.6 Global Single Nucleotide Polymorphism (SNP) Genotyping Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Single Nucleotide Polymorphism (SNP) Genotyping Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Single Nucleotide Polymorphism (SNP) Genotyping Market by Type
  1. 4.1 Single Nucleotide Polymorphism (SNP) Genotyping Type Introduction
  2. 4.1.1 Transversion
  3. 4.1.2 Transition
  4. 4.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type
  5. 4.2.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (2021-2032)
  7. 4.2.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type (2021-2032)
5 Single Nucleotide Polymorphism (SNP) Genotyping Market by Application
  1. 5.1 Single Nucleotide Polymorphism (SNP) Genotyping Application Introduction
  2. 5.1.1 Diagnostics
  3. 5.1.2 Animal
  4. 5.1.3 Plant
  5. 5.1.4 Research
  6. 5.1.5 Others
  7. 5.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application
  8. 5.2.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (2021-2032)
  10. 5.2.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application (2021-2032)
6 Single Nucleotide Polymorphism (SNP) Genotyping Regional Value Analysis
  1. 6.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2021-2032)
  3. 6.2.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region: 2021-2026
  4. 6.2.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2021-2032)
  7. 6.3.2 North America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2021-2032)
  10. 6.4.2 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2021-2032)
  16. 6.6.2 South America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Country, 2025 VS 2032
7 Single Nucleotide Polymorphism (SNP) Genotyping Country-level Value Analysis
  1. 7.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (2021-2032)
  3. 7.2.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (2021-2026)
  4. 7.2.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Illumina
  2. 8.1.1 Illumina Company Information
  3. 8.1.2 Illumina Business Overview
  4. 8.1.3 Illumina Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Illumina Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  6. 8.1.5 Illumina Recent Developments
  7. 8.2 Affymetrix
  8. 8.2.1 Affymetrix Company Information
  9. 8.2.2 Affymetrix Business Overview
  10. 8.2.3 Affymetrix Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Affymetrix Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  12. 8.2.5 Affymetrix Recent Developments
  13. 8.3 Applied Biosystems
  14. 8.3.1 Applied Biosystems Company Information
  15. 8.3.2 Applied Biosystems Business Overview
  16. 8.3.3 Applied Biosystems Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Applied Biosystems Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  18. 8.3.5 Applied Biosystems Recent Developments
  19. 8.4 Agilent Technologies
  20. 8.4.1 Agilent Technologies Company Information
  21. 8.4.2 Agilent Technologies Business Overview
  22. 8.4.3 Agilent Technologies Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Agilent Technologies Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  24. 8.4.5 Agilent Technologies Recent Developments
  25. 8.5 Beckman Coulter
  26. 8.5.1 Beckman Coulter Company Information
  27. 8.5.2 Beckman Coulter Business Overview
  28. 8.5.3 Beckman Coulter Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Beckman Coulter Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  30. 8.5.5 Beckman Coulter Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Qiagen
  38. 8.7.1 Qiagen Company Information
  39. 8.7.2 Qiagen Business Overview
  40. 8.7.3 Qiagen Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Qiagen Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  42. 8.7.5 Qiagen Recent Developments
  43. 8.8 Luminex Corporation
  44. 8.8.1 Luminex Corporation Company Information
  45. 8.8.2 Luminex Corporation Business Overview
  46. 8.8.3 Luminex Corporation Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Luminex Corporation Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  48. 8.8.5 Luminex Corporation Recent Developments
  49. 8.9 Enzo Life Sciences
  50. 8.9.1 Enzo Life Sciences Company Information
  51. 8.9.2 Enzo Life Sciences Business Overview
  52. 8.9.3 Enzo Life Sciences Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Enzo Life Sciences Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  54. 8.9.5 Enzo Life Sciences Recent Developments
  55. 8.10 Bio-rad
  56. 8.10.1 Bio-rad Company Information
  57. 8.10.2 Bio-rad Business Overview
  58. 8.10.3 Bio-rad Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bio-rad Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  60. 8.10.5 Bio-rad Recent Developments
  61. 8.11 Sequenom
  62. 8.11.1 Sequenom Company Information
  63. 8.11.2 Sequenom Business Overview
  64. 8.11.3 Sequenom Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sequenom Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  66. 8.11.5 Sequenom Recent Developments
  67. 8.12 Ocimum Biosolutions
  68. 8.12.1 Ocimum Biosolutions Company Information
  69. 8.12.2 Ocimum Biosolutions Business Overview
  70. 8.12.3 Ocimum Biosolutions Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Ocimum Biosolutions Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  72. 8.12.5 Ocimum Biosolutions Recent Developments
  73. 8.13 GE Healthcare
  74. 8.13.1 GE Healthcare Company Information
  75. 8.13.2 GE Healthcare Business Overview
  76. 8.13.3 GE Healthcare Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  77. 8.13.4 GE Healthcare Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  78. 8.13.5 GE Healthcare Recent Developments
  79. 8.14 GenScript
  80. 8.14.1 GenScript Company Information
  81. 8.14.2 GenScript Business Overview
  82. 8.14.3 GenScript Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  83. 8.14.4 GenScript Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  84. 8.14.5 GenScript Recent Developments
  85. 8.15 Douglas Scientific
  86. 8.15.1 Douglas Scientific Company Information
  87. 8.15.2 Douglas Scientific Business Overview
  88. 8.15.3 Douglas Scientific Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Douglas Scientific Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  90. 8.15.5 Douglas Scientific Recent Developments
  91. 8.16 BGI
  92. 8.16.1 BGI Company Information
  93. 8.16.2 BGI Business Overview
  94. 8.16.3 BGI Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BGI Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  96. 8.16.5 BGI Recent Developments
  97. 8.17 Beijing Sunbiotech
  98. 8.17.1 Beijing Sunbiotech Company Information
  99. 8.17.2 Beijing Sunbiotech Business Overview
  100. 8.17.3 Beijing Sunbiotech Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Beijing Sunbiotech Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  102. 8.17.5 Beijing Sunbiotech Recent Developments
  103. 8.18 HuaGene Biotech
  104. 8.18.1 HuaGene Biotech Company Information
  105. 8.18.2 HuaGene Biotech Business Overview
  106. 8.18.3 HuaGene Biotech Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  107. 8.18.4 HuaGene Biotech Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  108. 8.18.5 HuaGene Biotech Recent Developments
  109. 8.19 Generay Biotech
  110. 8.19.1 Generay Biotech Company Information
  111. 8.19.2 Generay Biotech Business Overview
  112. 8.19.3 Generay Biotech Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Generay Biotech Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  114. 8.19.5 Generay Biotech Recent Developments
  115. 8.20 Benegene
  116. 8.20.1 Benegene Company Information
  117. 8.20.2 Benegene Business Overview
  118. 8.20.3 Benegene Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Benegene Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  120. 8.20.5 Benegene Recent Developments
  121. 8.21 Shanghai Biochip
  122. 8.21.1 Shanghai Biochip Company Information
  123. 8.21.2 Shanghai Biochip Business Overview
  124. 8.21.3 Shanghai Biochip Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Shanghai Biochip Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  126. 8.21.5 Shanghai Biochip Recent Developments
  127. 8.22 GENESKY
  128. 8.22.1 GENESKY Company Information
  129. 8.22.2 GENESKY Business Overview
  130. 8.22.3 GENESKY Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  131. 8.22.4 GENESKY Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  132. 8.22.5 GENESKY Recent Developments
  133. 8.23 HD Biosciences
  134. 8.23.1 HD Biosciences Company Information
  135. 8.23.2 HD Biosciences Business Overview
  136. 8.23.3 HD Biosciences Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Gross Margin (2021-2026)
  137. 8.23.4 HD Biosciences Single Nucleotide Polymorphism (SNP) Genotyping Product Portfolio
  138. 8.23.5 HD Biosciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst